As genetic alterations may cause tumorigenesis, we analyzed the patient-derived tumor tissues, compared the expression of LEDGF/p75 with tumor mutation analysis of prominent colorectal cancer biomarkers (KRAS, BRAF) and recognized a positive correlation in 75% (3/4) of patients with KRAS mutation and significantly increased LEDGF/p75 expression (Table 1). The gene discussed is KRAS; the disease is colorectal cancer.